Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Revolution Medicines (RVMD) EPS (Weighted Average and Diluted) (2020 - 2025)

Revolution Medicines has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at -$1.89 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$1.89 for Q4 2025, down 67.26% from a year ago — trailing twelve months through Dec 2025 was -$5.94 (down 65.92% YoY), and the annual figure for FY2025 was -$5.95, down 66.2%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$1.89 at Revolution Medicines, down from -$1.61 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for RVMD hit a ceiling of -$0.6 in Q2 2021 and a floor of -$1.89 in Q4 2025.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.87 (2022), compared with a mean of -$0.97.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): grew 15.28% in 2022 and later crashed 98.36% in 2023.
  • Revolution Medicines' EPS (Weighted Average and Diluted) stood at -$0.72 in 2021, then rose by 15.28% to -$0.61 in 2022, then plummeted by 98.36% to -$1.21 in 2023, then increased by 6.61% to -$1.13 in 2024, then tumbled by 67.26% to -$1.89 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$1.89 (Q4 2025), -$1.61 (Q3 2025), and -$1.31 (Q2 2025) per Business Quant data.